<DOC>
	<DOCNO>NCT00062686</DOCNO>
	<brief_summary>This study design determine efficacy oral dual kinase inhibitor treatment metastatic breast cancer tumor know overexpress ErbB2 refractory patient population .</brief_summary>
	<brief_title>GW572016 For Treatment Of Refractory Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Signed Informed Consent . Histologically confirm Stage IIIb IV breast cancer . Refractory breast cancer define progression metastatic setting prior therapy anthracyclines , taxanes capecitibine . Subjects document ErbB2 tumor overexpression must receive least 6 cycle trastuzumab . Documented disease progression recent treatment require . Archived tumor tissue available testing . Measurable lesion accord Response Evaluation Criteria In Solid Tumors ( RECIST ) . At least 3 week since prior cancer therapy except trastuzumab must discontinue least 2 week prior begin study drug . Bisphosphonate therapy initiate prior study entry allow , however , initiation bisphosphonates follow study entry allow . Able swallow retain oral medication . Cardiac ejection fraction within institutional normal range measure echocardiogram MUGA ( Multiple Gated Acquisition ) scan . Adequate kidney liver function . Adequate bone marrow function . Exclusion criterion : Pregnant lactating . Copies nadir scan and/or photographs tumor prior disease progression well scan document disease progression available review . Malabsorption syndrome , ulcerative colitis , disease significantly affect gastrointestinal function resection stomach small bowel . History malignancy . Serious medical psychiatric disorder would interfere patient '' safety inform consent . Active uncontrolled infection . Known history uncontrolled symptomatic angina , arrhythmias congestive heart failure . Known history clinical evidence leptomeningeal carcinomatosis . Active infection . Concurrent cancer therapy investigational therapy . Use oral IV steroid . Unresolved unstable serious toxicity prior therapy . Prior treatment ErbB1 and/or ERbB2 inhibitor trastuzumab .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Lapatinib</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>HERCEPTIN refractory</keyword>
</DOC>